Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Cardiol Therapeutics will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12, 2025, at 9:30 a.m. EDT in Boston, MA. The session will be available as a live webcast on the company's website, and a replay will be accessible for 90 days following the event. Cardiol Therapeutics is a clinical-stage life sciences company developing treatments for heart disease, including its primary drug candidate CardiolRx™ (cannabidiol) and the subcutaneous drug formulation CRD-38.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, has announced its participation in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference. The event will take place on August 12, 2025, at 9:30 a.m. EDT in Boston, MA. The session will be available as a live webcast on the company's website, with a replay accessible for 90 days following the event.

Cardiol Therapeutics is developing a range of innovative therapies to address various heart conditions. Its primary drug candidate, CardiolRx™ (cannabidiol) oral solution, is currently in clinical development for the treatment of heart disease. CardiolRx™ is recognized for its ability to inhibit the inflammasome pathway, which is involved in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The company has received Investigational New Drug Application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies on CardiolRx™ for recurrent pericarditis and acute myocarditis.

Additionally, Cardiol Therapeutics is developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure. This condition is a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

The Fireside Chat at Canaccord Genuity's conference will provide an opportunity for investors and financial professionals to gain insights into Cardiol Therapeutics' clinical pipeline and its potential impact on the treatment of heart disease. The session will be led by Cardiol's management team and will cover the company's focus on developing anti-inflammatory and anti-fibrotic therapies, as well as its ongoing clinical trials and future plans.

For further information about Cardiol Therapeutics, please visit [CardiolRx.com](https://www.cardiolrx.com).

References:
[1] https://www.biospace.com/press-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-canaccord-genuitys-45th-annual-growth-conference
[2] https://www.newsfilecorp.com/release/261449/Cardiol-Therapeutics-Announces-Topline-Results-from-the-Phase-II-ARCHER-Trial-of-CardiolRxTM-in-Acute-Myocarditis